According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP) released on 4 September 2017, the agency is currently reviewing 24 applications for marketing approval in the EU for generics. The applications include one for a generic version of Glivec (imatinib), one for a generic version of Alimta (pemetrexed) and one for a generic version of Advagraf/Modigraf (tacrolimus), for which there are already generics approved by the EMA for all EU countries, see Table 1.

Table 1: Generics under review by EMA*

First-time pan-European generics under review by EMA include one for a generic of Shire’s platelet overproduction medicine Agrylin/Xagrid (anagrelide), one for a generic of Indivior’s opioid treatment Suboxone (buprenorphine/naloxone), one for a generic version of Emcure Pharmaceuticals chemotherapy drug BiCNU (carmustine), two for generic versions of Janssen-Cilag’s HIV treatment Prezista (darunavir), one for a generic version of Apotex’s iron overload in Thalassaemia treatment Ferriprox (deferiprone), one for a generic version of Janssen-Cilag/ Teva’s Caelyx/ Myocet (doxorubicin), one for a generic version of Gilead Sciences HIV treatment Atripla (efavirenz/emtricitabine/tenofovir disoproxil ), one for a generic version of AstraZeneca’s breast cancer treatment Faslodex (fulvestrant), one for a generic version of AstraZeneca’s lung cancer treatment Iressa (gefitinib), one for a generic version of Shire’s corticosteroid Plenadren (hydrocortisone), one for a generic version of Celgene’s Revlimid (lenalidomide), one for generic versions of Actelion’s Gaucher disease treatment Zavesca (miglustat), one for a generic of Sankyo’s opioid treatment Narcan (naloxone), one for a generic version of Swedish Orphan Biovitrum International’s treatment for hereditary tyrosinemia type 1 Orfadin (nitisinone), one for a generic version of Celgene’s Abraxane (paclitaxel), one for a generic version of Daiichi Sankyo’s angina treatment Efient (prasugrel), one for AbbVie’s HIV treatment Norvir (ritonavir), one for a generic version of UCB’s Parkinson’s disease treatment Leganto/Neupro (rotigotine), one for a generic version of Janssen Pharmaceutica’s potent opioid anaesthetic Sufenta (sufentanil) and one for a generic version of Lundbeck’s epilepsy drug Sabril/Sabrilex (vigabatrin).

Since the last report entitled ‘Generics applications under review by EMA – April 2017’ by GaBI Online, EMA has approved one generic version of Orphan Europe’s amino acid metabolism treatment Carbaglu (carglumic acid), one for a generic version of Gilead Sciences HIV treatment Atripla (efavirenz/emtricitabine/tenofovir disoproxil), two for generic versions of Bristol-Myers Squibb’s hepatitis B virus treatment Baraclude (entecavir), one for a generic version of TAP Pharmaceuticals/Ipsen’s gout treatment Adenuric (febuxostat), one for a generic version of UCB Pharma’s epilepsy medicine Vimpat (lacosamide), one for a generic version of Swedish Orphan Biovitrum International’s treatment for hereditary tyrosinemia type 1 Orfadin (nitisinone) and one for a generic of Pfizer’s antibiotic Tygacil (tygecycline).

Related articles
Generics applications under review by EMA – April 2017 

Biosimilars applications under review by EMA – April 2017

References
1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Sep 15]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-generics
2. GaBI Online - Generics and Biosimilars Initiative. Registration procedures for generic drugs in the EU [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Sep 15] Available from: www.gabionline.net/Reports/Registration-procedures-for-generic-drugs-in-the-EU

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.